Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective.

J Thorac Imaging

Department of Medicine, Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC.

Published: July 2016

Treatment advances have improved outcomes in patients with lung cancer, with a number of targeted therapies and immunotherapies now approved for patients with metastatic disease. Along with longer survival, modern treatment paradigms have increased therapeutic decision-making complexity underscoring informative imaging as paramount in guiding clinical care. In this review, we summarize challenges the thoracic oncologist encounters in common clinical settings. In addition, we explore unmet needs for future investigations with particular focus on positron emission tomography technology and immunotherapies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461391PMC
http://dx.doi.org/10.1097/RTI.0000000000000219DOI Listing

Publication Analysis

Top Keywords

lung cancer
8
imaging advanced
4
advanced non-small
4
non-small cell
4
cell lung
4
cancer medical
4
medical oncology
4
oncology perspective
4
perspective treatment
4
treatment advances
4

Similar Publications

We demonstrate that performing anatomical pulmonary resection by video-assisted thoracoscopic surgery without staplers or energy devices is feasible. This technique is an alternative for surgeons with limited access to expensive technologies.

View Article and Find Full Text PDF

Diagnosis of lung cancer using salivary miRNAs expression and clinical characteristics.

BMC Pulm Med

January 2025

Universal Scientific Education and Research Network (USERN), Tehran, Iran.

Objective: Lung cancer (LC), the primary cause for cancer-related death globally is a diverse illness with various characteristics. Saliva is a readily available biofluid and a rich source of miRNA. It can be collected non-invasively as well as transported and stored easily.

View Article and Find Full Text PDF

The association between Chlamydia pneumoniae infection and prognosis in lung cancer patients: a prospective study.

BMC Infect Dis

January 2025

Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, China.

Background: The prognostic value of Chlamydia pneumoniae (Cpn) infection in postoperative lung cancer patients remains unclear. This study aimed to evaluate the association between Cpn infection and survival in lung cancer patients.

Methods: This study included 309 newly diagnosed primary lung cancer patients from three hospitals in Fuzhou, China.

View Article and Find Full Text PDF

The role of Box A of HMGB1 in producing γH2AX associated DNA breaks in lung cancer.

Sci Rep

January 2025

Center of Excellence in Molecular Genetics of Cancer and Human Diseases, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

An ideal chemotherapeutic agent damages DNA, specifically in cancer cells, without harming normal cells. Recently, we used Box A of HMGB1 plasmid as molecular scissors to produce DNA gaps in normal cells. The DNA gap relieves DNA tension and increases DNA strength, preventing DNA double-strand breaks (DSBs).

View Article and Find Full Text PDF

Trousseau's syndrome is a thromboembolic disorder associated with malignancies, with cerebral infarction and hemorrhage representing common central nervous system complications in patients with cancer. This report details the diagnosis and treatment of a patient with gastric adenocarcinoma at our institution who concurrently developed cerebral infarction and subarachnoid hemorrhage. We performed a comprehensive literature review in the Wanfang and PubMed databases, searching for relevant studies on Trousseau's syndrome, cerebral embolism, and subarachnoid hemorrhage.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!